Capital Guardian Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

Capital Guardian Trust’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-398	Closed	-$55K	–	495
2018 Q3	$55K	Buy	+398	New	+$49.9K	﹤0.01%	329
2017 Q2	–	Sell	-50	Closed	-$6K	–	598
2017 Q1	$6K	Hold	50	–	–	﹤0.01%	577
2016 Q4	$6K	Hold	50	–	–	﹤0.01%	619
2016 Q3	$6K	Hold	50	–	–	﹤0.01%	626
2016 Q2	$6K	Hold	50	–	–	﹤0.01%	601
2016 Q1	$7K	Sell	50 -201	-80%	-$29.5K	﹤0.01%	651
2015 Q4	$48K	Hold	251	–	–	﹤0.01%	458
2015 Q3	$39K	Hold	251	–	–	﹤0.01%	453
2015 Q2	$45K	Hold	251	–	–	﹤0.01%	452
2015 Q1	$43K	Hold	251	–	–	﹤0.01%	465
2014 Q4	$46K	Hold	251	–	–	﹤0.01%	411
2014 Q3	$42K	Hold	251	–	–	﹤0.01%	411
2014 Q2	$39K	Buy	251 +50	+25%	+$7.89K	﹤0.01%	404
2014 Q1	$31K	Sell	201 -14	-7%	-$2.23K	﹤0.01%	408
2013 Q4	$29K	Hold	215	–	–	﹤0.01%	417
2013 Q3	$25K	Hold	215	–	–	﹤0.01%	392
2013 Q2	$20K	Buy	+215	New	+$20.7K	﹤0.01%	390

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital Guardian Trust's ALXN Position: Q4 2018 in Review

Capital Guardian Trust sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 398 shares — an estimated $55K sold.

Capital Guardian Trust first reported a position in ALXN in Q2 2013 and held it in 17 quarters. The position peaked at $55K in Q3 2018. 609 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

Capital Guardian Trust reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Capital Guardian Trust sold 398 Alexion Pharmaceuticals shares in Q4 2018, an estimated $55K.
Capital Guardian Trust first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Capital Guardian Trust's Alexion Pharmaceuticals position peaked at $55K in Q3 2018.
609 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Capital Guardian Trust's 13F filing for Q4 2018, filed 14 Feb 2019.